Karyopharm’s Xpovio In Multiple Myeloma Priced At $22,000 Per Four-Week Cycle

Immediate interaction with US FDA after stressful advisory committee facilitated accelerated approval in fourth-line myeloma, company says. Four different dosing regimens will be priced at $22,000 for four weeks.